Bank of Montreal Can Buys 1,274 Shares of Vaxcyte, Inc. $PCVX

Bank of Montreal Can boosted its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 4.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,547 shares of the company’s stock after purchasing an additional 1,274 shares during the period. Bank of Montreal Can’s holdings in Vaxcyte were worth $1,026,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Envestnet Asset Management Inc. grew its holdings in shares of Vaxcyte by 75.4% in the first quarter. Envestnet Asset Management Inc. now owns 96,600 shares of the company’s stock worth $3,648,000 after purchasing an additional 41,517 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Vaxcyte by 10.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company’s stock worth $112,000 after acquiring an additional 293 shares during the last quarter. Xponance Inc. grew its holdings in Vaxcyte by 4.7% in the 1st quarter. Xponance Inc. now owns 9,320 shares of the company’s stock worth $352,000 after acquiring an additional 415 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of Vaxcyte by 190.6% in the first quarter. New York State Common Retirement Fund now owns 137,440 shares of the company’s stock valued at $5,190,000 after acquiring an additional 90,145 shares during the period. Finally, IFP Advisors Inc raised its stake in shares of Vaxcyte by 376.4% during the first quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock valued at $62,000 after acquiring an additional 1,306 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. BTIG Research reissued a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a research note on Monday, November 10th. The Goldman Sachs Group began coverage on Vaxcyte in a research report on Friday, September 12th. They issued a “neutral” rating and a $38.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday, October 14th. Finally, Cowen restated a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $102.00.

Vaxcyte Trading Up 6.9%

Shares of Vaxcyte stock opened at $48.69 on Friday. The firm has a market capitalization of $6.37 billion, a P/E ratio of -10.06 and a beta of 1.07. The business has a fifty day simple moving average of $39.48 and a two-hundred day simple moving average of $35.44. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $94.76.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same period in the previous year, the firm earned ($0.83) EPS. Analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.